Blueprint/Sanofi Drug Shows Long-Term Benefit in Rare Disease
Blueprint Medicines, a Sanofi company, announced new four-year data showing its drug AYVAKIT provides sustained benefit and long-term safety for patients with indolent systemic mastocytosis. The PIONEER study data, presented at the 2026 AAAAI Annual Meeting, reinforces the drug's effectiveness in treating the rare hematologic disorder. A real-world study also highlighted improvement across various symptoms.
Indolent systemic mastocytosis (ISM) is a chronic hematologic disorder where the body produces too many mast cells. In about 95% of cases, the disease is driven by a specific mutation known as KIT D816V, which causes these immune cells to accumulate in the skin, bone marrow, and internal organs. This buildup leads to a wide range of debilitating and often unpredictable symptoms, from skin lesions and severe diarrhea to brain fog and bone pain. Before targeted therapy, treatment for ISM focused on managing symptoms with a regimen of antihistamines, leukotriene inhibitors, and mast cell stabilizers. While helpful for some, this approach does not address the underlying cause of the disease—the overproduction of mast cells. AYVAKIT (avapritinib) is the first therapy designed to potently and selectively inhibit the KIT D816V mutation, marking a shift from supportive care to a disease-modifying treatment. The long-term PIONEER study, with a median follow-up of nearly four years (46.5 months), demonstrated the drug's sustained impact. For patients who experienced frequent diarrhea and remained on the drug for at least four years, there was a 65.6% median reduction in the frequency of these episodes. The data, presented at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, also showed continued improvements in overall symptoms and quality of life. Beyond symptom control, AYVAKIT has shown effects that suggest it modifies the disease itself. After three years of treatment, patients showed increased bone mineral density, addressing one of the long-term health complications of ISM. The long-term safety profile remains favorable, with a low discontinuation rate of 3% due to treatment-related adverse events over the four-year period. The U.S. Food and Drug Administration (FDA) approved AYVAKIT for indolent systemic mastocytosis in May 2023. This followed its initial approval in June 2021 for advanced systemic mastocytosis. The therapy was originally developed by Blueprint Medicines, which was later acquired by Sanofi in a deal announced in 2025 to bolster Sanofi's portfolio in rare immunological diseases.
